Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib DDI with Digoxin and Rosuvastatin
NCT02106845Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of regorafenib in Advanced malignant solid neoplasm (AMSN) (2 arms), sponsored by Bayer. Primary endpoints: Area under the plasma concentration-time curve from time zero to 24 hours and Maximum drug concentration in plasma. Started Apr 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
Advanced malignant solid neoplasm (AMSN)
Beyond the preview
Go deeper on NCT02106845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106845.